Front. Med.Frontiers in MedicineFront. Med.2296-858XFrontiers Media S.A.10.3389/fmed.2021.643175MedicineOriginal ResearchProduction of Mass-Separated Erbium-169 Towards the First Preclinical in vitro InvestigationsTalipZeynep1*BorgnaFrancesca1MüllerCristina12UlrichJiri3DucheminCharlotte45RamosJoao P.45StoraThierry4KösterUlli6NedjadiYoucef7GadelshinVadim489FedosseevValentin N.4JugetFrederic7BailatClaude7FankhauserAdelheid10WilkinsShane G.4LambertLaura4MarshBruce4FedorovDmitry11ChevallayEric4FernierPascal4SchibliRoger12van der MeulenNicholas P.131Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland2Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland3Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, Switzerland4European Organization for Nuclear Research (CERN), Geneva, Switzerland5Institute for Nuclear and Radiation Physics, Catholic University of Leuven, Leuven, Belgium6Institut Laue-Langevin, Grenoble, France7Institute of Radiation Physics, University Hospital and University of Lausanne, Lausanne, Switzerland8Institute of Physics, Johannes Gutenberg University, Mainz, Germany9Institute of Physics and Technology, Ural Federal University, Yekaterinburg, Russia10Analytic Radioactive Materials, Paul Scherrer Institute, Villigen, Switzerland11Petersburg Nuclear Physics Institute, National Research Center Kurchatov Institute, Gatchina, Russia
Edited by: Anil Kumar Mishra, Institute of Nuclear Medicine & Allied Sciences (DRDO), India
Reviewed by: John W. Babich, Cornell University, United States; Nicolas Lepareur, Centre Eugène Marquis, France
*Correspondence: Zeynep Talip zeynep.talip@psi.ch
This article was submitted to Nuclear Medicine, a section of the journal Frontiers in Medicine
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.
Er-169electromagnetic isotope separationlanthanide-separationactivity standardizationin vitro studieslaser resonance ionizationSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung10.13039/501100001711Swiss Cancer Research Foundation10.13039/501100013362Introduction
Radiolanthanides are of particular interest in the field of nuclear medicine, offering attractive decay properties for both diagnosis and therapy (1–6). One of the most intriguing features of the radiolanthanides, other than having promising physical decay properties, is that they have similar chemical characteristics, and analogous coordination chemistry, which allows one to perform comparative pre-clinical studies. A significant disadvantage of lanthanides, however, is that they are difficult to chemically separate and isolate.
Currently, the β−-emitting 177Lu is used on a routine basis in clinics for targeted radionuclide therapy. The Center of Radiopharmaceutical Sciences (CRS) at Paul Scherrer Institute (PSI) has recently introduced 161Tb as a potentially better alternative to 177Lu due to its co-emission of conversion and Auger electrons (Table 1). There is good reason to assume that conversion and Auger electrons emitted by 161Tb, in addition to β−-particles, have an additive therapeutic effect (7). However, further studies are needed to investigate the contribution of conversion and Auger electrons in more detail. In this regard, the use of radionuclides with either β−- or Auger-electron emission would be ideal to investigate. The matched pair of 169Er (pure β−-particle emitter) with the pure Auger-electron emitter 165Er can, thus, represent an ideal model system to evaluate the additive therapeutic effect of Auger electrons on targeted β− therapy.
Comparison of decay properties and Auger electron/Conversion electron energies of 161Tb, 169Er, and 165Er, respectively.
Radionuclide
t1/2
βav- (keV)
Electrons
Energy (keV)
Intensity (%)
161Tb
6.96 d
154
CE K
3.4
17.5
Auger L
5.2
87.9
CE L
16.6
41.0
CE K
20.8
5.7
CE M
23.6
9.2
169Er
9.39 d
100
CE M
6.1
36.0
CE N
7.9
8.2
165Er
10.36 h
_
Auger L
5.3
65.6
Auger K
38.4
4.8
Only the high intensities are shown (data are taken from 1).
169Er (t1/2 = 9.39 d, Eβav- = 100 keV1) and 165Er (t1/2 = 10.36 h) have promising decay properties toward radionuclide therapy of metastasized cancer diseases (Table 1). Dosimetry calculations showed that 169Er displayed higher tumor-to-normal-tissue absorbed dose ratio (TND) values than the currently clinically-used radiolanthanide 177Lu (8) for tumor sizes from 102 to 10−9 g (3), which is ascribed to its soft β−-radiation and the negligible photon dose (only 0.017 eV per decay1). Its low-energy β−-particles have an average soft tissue range of 0.3 mm (9). Moreover, the relatively long half-life of 169Er is considered as an additional advantage to avoid activity loss during transport and storage. On the other hand, 165Er is an attractive radiolanthanide for pure Auger-electron therapy. It decays by electron capture, followed by the emission of Auger electrons without accompanying γ-radiation, but emission of X-rays with an average energy of 48.8 keV. Systematic pre-clinical studies, by combining 169Er and 165Er with varying activity ratios, would help in understanding the additive therapeutic effect of Auger electrons, which requires the availability of these radionuclides in a suitable quality for pre-clinical studies.
Erbium-169 is currently produced by neutron irradiation of highly-enriched (98.2%) 168Er2O3 targets in nuclear reactors. In this way, it can only be produced with low specific activity in the carrier-added form due to the relatively low neutron capture cross-section of 168Er (σ: 2.3 barn) (10). To date, 169Er has only been used as a colloid in citrate form for the treatment of chronic rheumatoid arthritis, inflamed synovium by means of irradiation and to improve joint function (9, 11–18). For this purpose, low-specific activities are acceptable. However, for tumor-targeted radionuclide therapy, 169Er is required as a high-specific activity product.
A combination of mass and chemical separation, to obtain high-purity radionuclides for nuclear medicine applications, represents an innovative approach to achieve this goal (19–21). As proof-of-principle experiments, the ISOLDE (Isotope Separation On-Line) facility at CERN was used for the mass separation of medically-researched terbium radionuclides (22–25). Neutron-deficient diagnostic and therapeutic terbium radionuclides [152Tb (19, 20, 26–29), 155Tb (27, 30), and 149Tb (21, 27, 31, 32)], were separated at ISOLDE and, after chemical separation at PSI, utilized for pre-clinical in vitro and in vivo studies. Similar mass separation techniques have recently been used at the CERN-MEDICIS facility with off-line mass separation capabilities (33–40). An 169Er mass separation proof of concept (up to 17 MBq), obtained from reactor-irradiated enriched 168Er targets, was previously performed using an electromagnetic isotope separation (EMIS) method (37).
In the present work, an offline mass separation technique was used in combination with a resonance laser ion source (34, 39, 41, 42), which ensured the increase of efficiency and selectivity for 169Er. The activities produced were sufficient to perform one preliminary in vitro assay. Previously, ionization efficiency values in the order of 20–50% (on mass separators equipped with laser ion sources) were reported for holmium, dysprosium and lutetium (38, 43, 44). Similar results were also obtained at the CERN-MEDICIS facility for 167Tm (45), indicating room for separation efficiency improvements for 169Er. In addition to higher separation efficiencies, longer irradiation times and minimum activity loss during radiochemical separation and transport will allow one to produce 169Er in much higher activities for comprehensive pre-clinical studies and, to evaluate the potential of this novel radionuclide for future clinical applications.
This systematic study consisted of several steps, namely, irradiation, mass separation, radiochemistry, quality control, and radiolabeling, to obtain a standard procedure for the production of 169Er in view of its use for receptor-targeted radionuclide therapy (Figure 1). After the mass separation process, the subsequent chemical separation method was developed to obtain 169Er in a solution of sufficient quality to enable radiolabeling of tumor-targeting agents. The activity standardization of 169Er was completed using the triple-to-double-coincidence ratio (TDCR) technique to perform precise activity measurements (46). A preliminary in vitro experiment was carried out to assess tumor cell viability upon exposure to 169Er-labeled PSMA-617 using cancer cells expressing the prostate-specific membrane antigen (PSMA).
Stepwise production of 169Er for receptor-targeted radionuclide therapy (chemical set up image was taken from https://thenounproject.com/ under the license number: ch_0GVAv9Ol-QUEvnWfJrWcOvos9).
Materials and MethodsProduction of Carrier-Added <sup>169</sup>Er
Enriched 168Er2O3 (98.0%, ISOFLEX, USA and 98.2% Trace Sciences Int., Canada) was used as target material for the production of 169Er via the 168Er(n, γ)169Er nuclear reaction. The 168Er2O3 samples (7.9–14.2 mg) were sealed in quartz ampoules and irradiated in the V4 irradiation position of the high-flux reactor at Institute Laue–Langevin (ILL), Grenoble, France (thermal neutron flux ≈ 1.1 1015 n.cm2.s−1, irradiation time: 7 days, 169Er theoretical yield: 25-48 GBq). After irradiations, the ampoules were transported to the CERN-MEDICIS facility for the offline mass separation of A = 169.
Carrier-added 169Er, supplied as a colloidal suspension of 169Er-citrate from Curium (Swiss distributor: b.e. imaging GmbH), was used as a representative sample for post-irradiation and after chemical separation for activity standardization. The list of all the characterized samples, using different techniques, is given in Table 2.
The list of the used and characterized samples.
Samples
Characterization
Enriched 168Er2O3 (Isoflex)
ICP-MS
Enriched 168Er2O3 (Trace Sciences)
ICP-MS
Carrier-added 169Er (b.e. Imaging)
Activity standardization (TDCR)
Seven samples after mass separation
γ-ray spectrometry
Seven samples after mass and chemical separation
Quality control analyses (section Quality Control)
Mass Separation
MEDICIS' Laser Ion Source for Separator Assembly (MELISSA) (39) was utilized for the offline mass separation of 169Er. 169Er-containing ampoules were opened and transferred into an ISOLDE standard tantalum target container (25). The container was connected to a rhenium ion source via a transfer line. The extraction electrode was positioned after an acceleration gap of 60 mm from the ion source's exit. Respective currents of 250 A and 300 A were applied to heat the target, as well as the line, and to allow for preliminary optimization steps on stable 168Er. 169Er was extracted from targets that were heated up to 2,200°C (corresponding to a current of 730 A). The current laser setup consists of two Z-cavity Ti:sapphire lasers, designed by Mainz University (47), each pumped by a dedicated commercial InnoLas Nanio 532-18-Y laser system. The two-step laser resonance ionization scheme for erbium was used; the optimized wavelengths during the collections were 24943.95 cm−1 for TiSa n°2 and 24337.32 cm−1 for TiSa n°1, as reported in (37, 44, 48). The ions were electrostatically accelerated to 60 keV and mass-separated with a magnetic sector field.
The mass-separated A = 169 beam, containing 169Er, was implanted into a solid catcher (zinc-coated gold foil). Gold foils (thickness: 0.1 mm, purity: 99.95%, Goodfellow Cambridge Ltd. Huntingdon, UK) were coated with 500 nm Zn (99.995% Zn granulate from Neyco, France) layer using physical vapor deposition (PVD) technique. In total, seven mass-separated samples were shipped to PSI for chemical separation, quality control, and an in vitro proof-of-concept experiment.
Radiochemical Separation
The radiochemical separation method was developed for the separation of macro amounts of Zn and as well as isobaric 169Yb and 169Tm from the desired 169Er. The gold foil obtained from CERN (Supplementary Figure 1) was introduced into a reaction vial and the 169Er-implanted Zn layer dissolved in 7 mL 6 M HNO3. The resulting solution was directly loaded onto a column containing N,N,N′,N′-tetra-n-octyldiglycolamide, non-branched resin (DGA, particle size 50–100 μm, TrisKem International, France; volume 0.08 mL), which is based on tetraoctlyldigycolamide as sorbent. The column was rinsed several times with 6.0 M HNO3 and the Zn concentration in each fraction determined using an Agilent 5110 Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES).
After removal of the macro amounts of Zn; Er, Yb, and Tm were eluted using 0.05 M HCl and loaded onto a column containing Sykam macroporous cation exchange resin (Sykam Chromatographie Vertriebs GmbH, Germany; particle size 12–22 μm, NH4+ form; column volume: 2.5 mL). Separation of 169Yb and 169Er was performed with 0.06–0.08 M α-hydroxyisobutyric acid (α-HIBA, Sigma-Aldrich GmbH, Germany) using the Sykam cation exchange resin separation system. Subsequently, LN3 resin (Triskem International, France; column volume: 0.04 mL) was used to remove the complexing agent (α-HIBA), be an additional means of Zn removal and to obtain the final product in chloride form. The use of 2 mL 0.02 M HCl removed the Zn from the system, prior to the elution of 169Er (1 mL 2.0 M HCl).
As an extra, and final, separation step, 169Er 1 mL 2 M HCl solution was passed through a TK200 resin [Triskem International, France; based on TriOctylPhosphine Oxide (TOPO), column volume: 0.06 mL], for the complete removal of Zn from the final product. The eluant was, then, heated until dryness and redissolved in 250 μL 0.05 M HCl solution, which was used for the radiolabeling of PSMA-617.
Quality ControlActivity Standardization
Gamma-ray spectra of the gold foils were taken before and after leaching of the Zn layer, using a high-purity germanium (HPGe) detector (Canberra, France), in combination with the Inter-Winner software package (version 7.1, Itech Instruments, France) (Supplementary Figure 2).
Purified 169Er in 0.1 M HCl (stock solution) was divided into two parts, named Er1 and Er2, respectively (Figure 2). They were accurately weighed using a Mettler-Toledo XS225DU balance. Sample Er1 was sent to the Institute of Radiation Physics (IRA, Lausanne) for activity standardization using the TDCR technique. The activity concentration of the Er1 solution was used to prepare 169Er quench series to calibrate LSC using Er2 solution (Supplementary Figure 3A). The counting efficiency for typical samples was ~97%.
Scheme of the samples used for the activity standardization and calibration of the LSC (liquid scintillation counting).
The 169Er activity measurements of the mass-separated samples were performed after chemical separation using liquid scintillation counting (LSC; LSC Packard Tri-Carb 2250 CA) (Supplementary Figure 3B). Further details about activity standardization measurements of 169Er are described in the Supplementary Material.
Radionuclidic Purity
After chemical separation, the radionuclidic purity of the samples was determined using a HPGe detector, as described in section Activity Standardization.
Isotopic Ratio Measurement
Enriched 168Er2O3 (98.0%, ISOFLEX, USA, and 98.2% Trace Sciences Int. Canada) and four mass-separated 169Er samples (S1-S4) were analyzed using a Thermo Fisher Scientific Sector Field Inductively Coupled Plasma Mass Spectrometer (SF-ICP-MS) Element II®. The measurement solutions were prepared from Suprapur nitric acid (Merck GmbH, Germany) and Milli-Q-water, which were also measured and subtracted as blank. Rhenium standard solution (10 mg/L, ESI, Elemental Scientific, Omaha, NE, USA) was added to each measurement solution as an internal standard, to account for plasma instabilities during the measurement. Instrument settings, such as gas flows, were tuned daily.
The measurement was performed in low-resolution mode, scanning the masses 149–170 and for the internal standard 185 and 187. A standard solution containing stable isotopes of rare earth elements, including Er, was measured at the start of the measurement sequence as a performance check.
Chemical Purity
The chemical purity of the sample was determined using ICP-OES (Agilent ICP-OES 5110). Zn- and Er-containing standard solutions (0.1, 0.5, 1, 5 ppm, respectively) were prepared in 2% HNO3 (Merck Suprapur), using Sigma-Aldrich TraceCERT®, 1,000 mg/L Er and Zn ICP standards.
Radiochemical Purity
Radiochemical purities of Sample 5 and Sample [6-7 (dissolved together to obtain higher activity)] were determined by radiolabeling, using PSMA-617 as a model compound. The percentage of 169Er-PSMA-617 obtained was determined using High-Performance Liquid Chromatography (HPLC) with a C-18 reversed-phase column (XterraTM MS, C18, 5 μm, 150 × 4.6 mm; Waters). The mobile phase consisted of MilliQ water containing 0.1% trifluoracetic acid (A) and acetonitrile (B) with a gradient of 95% A and 5% B to 20% A and 80% B over a period of 15 min at a flow rate of 1.0 mL/min. A sample of the radiolabeling mixture was diluted in MilliQ water containing sodium diethylenetriamine-pentaacetic acid (Na-DTPA; 50 μM) prior to injection into the HPLC instrument.
System evaluation
169Er has a negligible emission of photon radiation. Therefore, before labeling experiments, the detection of 169Er using a radio-HPLC detector was assessed by comparison to 177Lu. Supplementary Figure 4 shows the comparison of the HPLC chromatograms of ~0.3 MBq free activity for 169Er and 177Lu, respectively. Before injecting the samples, the HPLC column was cleaned by running several blanks using DTPA solution to ensure the detection of 169Er.
Preparation of radioligands
PSMA-617 (ABX GmbH, Radeberg, Germany) was labeled with 169Er under standard conditions at a molar activity of 10 MBq/nmol. A stock solution of PSMA-617 (1 mM) was mixed with a solution of 169Er in 0.05 M HCl and the pH adjusted to 4.0 with the addition of sodium acetate solution (0.5 M, pH 8). The reaction mixture was incubated for 20 min at 95°C. Quality control of 169Er-PSMA-617 was performed using HPLC, as reported above.
As a control compound, PSMA-617 was labeled with 177Lu (carrier-free in 0.04 M HCl; ITM, Germany) at a molar activity of 10 MBq/nmol, according to a previously-published procedure (49). Quality control of 177Lu-PSMA-617 was also performed using HPLC.
Sublines of the androgen-independent PC-3 human prostate cancer cell line, PSMA-positive, PC-3 PIP tumor cells were kindly provided by Prof. Martin Pomper (Johns Hopkins University School of Medicine, Baltimore, MD, USA) (50). The cells were grown in RPMI cell culture medium supplemented with 10% fetal calf serum, L-glutamine and antibiotics, as well as puromycin (2 μg/mL), to maintain PSMA expression (51–53).
A tumor cell viability assay was performed using PC-3 PIP/flu tumor cells treated with 169Er-PSMA-617 and 177Lu-PSMA-617 (0.01–10 MBq/mL), respectively. The assay was performed according to a previously-published method using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (7). PC-3 PIP tumor cells (2,500 cells in 200 μL RPMI medium with supplements) were seeded in 96-well plates and incubated overnight (37°C; 5% CO2) to allow adhesion of the tumor cells. 169Er-PSMA-617 or 177Lu-PSMA-617 (10 MBq/nmol, the highest achievable molar activity for 169Er-PSMA-617) were diluted in RPMI medium without supplements to an activity concentration of 0.1–10 MBq/mL. The tumor cells were washed with 200 μL phosphate buffered saline (PBS, pH 7.2) prior to the addition of the radioligand dilutions (200 μL/well). Control cells were sham-treated with RPMI medium without the addition of radioligands. After a 4 h incubation period (37°C; 5% CO2), tumor cells were washed with 200 μL PBS and fresh PRMI medium (with supplements) was added to each well. Tumor cell viability was determined after 6 days of incubation at 37°C, 5% CO2. MTT reagent (5 mg/mL in PBS, 30 μL per well) was added to each well, followed by incubation of the well plates for 4 h. The dark-violet formazan crystals were dissolved with 200 μL dimethyl sulfoxide. The absorbance was measured at 560 nm using a microplate reader (Victor X3, Perkin Elmer). Cell viability was quantified by expressing the absorbance of the test samples as a percentage of the absorbance of untreated tumor cell samples, which was set to 100%.
ResultsIrradiation and Mass Separation
In total, five ampoules containing 168Er2O3 were used for 169Er production at the ILL nuclear reactor, with a theoretical yield between 25 and 48 GBq. After the irradiations, the ampoules were transported to the CERN-MEDICIS facility. Supplementary Figure 5A shows the γ-ray spectrum of commercially-available carrier-added 169Er (supplied by b.e. Imaging GmbH) as a representative spectrum for post-irradiation. The product had a reported radionuclidic impurity ≤0.38% of the 169Er activity, with 177Lu (0.02%) the main impurity.
The mass 169 ion beam was implanted into seven solid catchers (two collections were performed for two ampoules). The mass separation was combined with resonant laser ionization to enhance element selectivity for the erbium ionization, as well as the overall separation efficiency. Thus, 169Er activities were increased up to a factor of four compared to the surface ionization technique (37). The presence of trace quantities of Yb (<400 ppm) in the target material (168Er2O3) led to the co-production of 169Yb (t1/2 = 32 d) due to the high thermal neutron capture cross-section of 168Yb (σ: 2400 b) (10). As a result, after the mass separation process, 169Yb (isobar of 169Er) was observed as a radionuclidic impurity (Supplementary Figure 5B). The average collection time was 63 hours, with separation efficiencies of up to 0.5%. To the best of our knowledge, to date, only a few measurements were reported for the emission probabilities of 169Er, with large discrepancies (20%) for the two lines at 109.8 and 118.2 keV (54). Moreover, 169Er has the same γ-ray peak (109.78 keV, 0.0013%) as 169Yb (109.78 keV, 17.39%) with much lower intensity (8), which made difficult to perform precise 169Er activity measurements of the samples by means of γ-ray spectrometry. Therefore, separation efficiencies were determined based on the theoretical initial and final 169Er activities measured using LSC (after chemical separation). Since activity loss during the ampoule opening and transferring were not taken into consideration, the actual separation efficiencies are expected to be higher than the reported values.
Radiochemical Separation
The zinc layer, containing the implanted 169Er activity and the isobar 169Yb, was dissolved from the gold foil. Cation and extraction chromatographic resins were used for the effective separation of 169Er from isobars and macro quantities of zinc to obtain chemically and radionuclidically pure 169Er. DGA extraction resin was used for the first separation step, which required the use of concentrated nitric acid as a loading solution for the separation of macro quantities of Zn from the lanthanides. ICP-OES results showed that traces of zinc (300 ppb) were retained on the resin (Supplementary Figure 6) and eluted together with 169Er and 169Yb using 0.05 M HCl. The separation of lanthanides (Er and Yb) was, subsequently performed using Sykam cation exchange resin. An example of the separation profile is presented in Figure 3A. The α-hydroxyisobutyric acid (α-HIBA), used as a complexing agent to separate lanthanides, was removed by passing the eluent through LN3 extraction resin. It was also important to use this resin to eliminate Zn from the desired product, as well as to concentrate the desired product in a small volume. This three-step separation process (DGA, Sykam, and LN3 resin) was initially applied to obtain 169Er with high radionuclidic and chemical purity. However, quality control analysis of the final product (section Quality Control) showed that a three-step separation process was not sufficient to reach the required high chemical purity. Thus, an additional purification step, using the TK200 resin, was added to separate the remaining Zn from the final product (Figure 3B).
(A) Separation profile of 169Yb and 169Er using Sykam cation exchange resin and α-HIBA as eluent, (B) scheme of the chemical separation process for the mass-separated 169Er samples.
Quality Control
Assessment of the quality control steps is crucial for the development of novel radionuclides toward nuclear medical applications (55). As part of the quality control processes, activity, radionuclidic purity, isotope ratio, radiochemical purity and chemical purity measurements were performed to evaluate the success of the mass and chemical separation methods (Figure 4). In total, seven 169Er samples were analyzed using different techniques (Table 3). Samples 6 and 7 were dissolved together to obtain higher activity toward an in-vitro experiment.
Quality control analyses applied to the 169Er samples after chemical separation (LSC, Liquid Scintillation counting, ICP-MS, Inductively Coupled Plasma Mass Spectrometry; HPLC, High-Performance Liquid Chromatography; ICP-OES, Inductively Coupled Plasma—Optical Emission Spectrometry).
Quality control analysis and results obtained for the mass-separated samples post-chemical processing.
S1
S2
S3
S4
S5
S6-7
Activity measurement (MBq)
52.9
23.4
8.59
4.70
73.2
93.4
Radionuclidic purity (%)
>99.9
>99.9
>99.9
>99.9
>99.9
>99.9
Isotopic ratio (168/169)
1.66
1.60
14.62
11.94
n.d
n.d
Chemical purity
n.d
n.d
n.d
n.d
0.49 μg Zn
n.d
Radiochemical purity (%)
n.d
n.d
n.d
n.d
0*
>98%
n.d., not determined.
The radiolabeling of PSMA-617 was not possible.
Activity Standardization
Gamma-ray spectrometry measurements were performed before and after dissolving the zinc layer from the gold foils to evaluate the fraction of the 169Er implanted into the zinc layer and the gold backing, respectively. Except for the first sample, the 169Er activities that remained on the gold foils were negligible.
In order to perform precise 169Er activity measurements, a purified 169Er solution was used for the activity standardization using the TDCR technique and its activity concentration was measured as 798.5 ± 5.9 kBq/g (0.33%, k = 1). The uncertainty budget of the measurement is given in Supplementary Table 1. An efficiency calibration curve was constructed based on the activity concentration determined by the TDCR technique and stored in the LSC software to enable routine activity measurements. Subsequently, activity measurements of all the purified 169Er samples were performed using calibrated LSC.
Radionuclidic Purity
Figure 5 shows an example of a γ-ray spectrum of 169Er after chemical separation. Thanks to the effective removal of 169Yb (Figure 3A), no radionuclidic impurity was determined after 15 days counting time. The background spectrum was taken shortly after the measurement to check for its interference. The two 169Er γ-ray peaks at 109 and 118 keV were observed (the inset of Figure 5), as well as the intense peaks at 50 keV and 57–59 keV, which correspond to the X-ray lines of 169Er.
Representative γ-ray spectrum of 169Er product after chemical separation (counting time: 15 days, sample detector distance: 15 cm) and background spectrum (counting time: 2 days). The inset shows a zoom of the two lines at 109 and 118 keV, respectively.
Isotopic Ratio
After the mass and chemical separation processes, four samples were analyzed to determine the mass 168 and 169 ratios using a Sector Field Inductively Coupled Plasma Mass Spectrometer (SF-ICP-MS). The results showed that the tail of 168Er was more pronounced in Samples 3 and 4 than Samples 1 and 2 (Table 3). Sample 5 and Sample 6-7 were not analyzed, since these samples were used for radiolabeling. The analytical method was validated by measuring the 168Er enriched materials, which were in good agreement with their certificate of analysis (CoA) (Supplementary Table 2).
Chemical and Radiochemical Purity
After the three-step separation process, Sample 5 was used to test the preparation of 169Er-PSMA-617 at a molar activity of 10 MBq/nmol. The radiolabeling of PSMA-617, failed due to the presence of 0.49 μg Zn impurity (determined by ICP-OES) competing with the 169Er for the DOTA chelator of PSMA-617.
To investigate the quantity of Zn that will affect the labeling efficiency, labeling experiments were performed with non-carrier-added 177Lu (as a surrogate for 169Er) and DOTANOC in the presence of different masses of non-radioactive Zn (Supplementary Figure 7). These experiments revealed that radiolabeling of the compound was not possible in the presence of ≥0.2 μg Zn. Thus, samples 6 and 7 were dissolved together and purified, utilizing TK200 resin to separate the remaining Zn.
Preparation of radioligand
Samples 6 and 7 were dissolved, combined, and used to prepare 169Er-PSMA-617 at a molar activity of 10 MBq/nmol with a radiochemical purity of >98% (Figure 6).
Representative HPLC radiochromatogram of 169Er-PSMA-617 prepared at 10 MBq/nmol, demonstrating the product peak and its retention time in minutes (tR = 8.6 ± 0.1 min) (pH: 4.5, T: 95°C, 20 min incubation).
<italic>In vitro</italic> Viability Studies
The radioligand 169Er-PSMA-617 was tested in a tumor cell viability assay (in vitro) to investigate its therapeutic potential in comparison to the clinically-established 177Lu-PSMA-617. Exposure of PC-3 PIP tumor cells to 169Er-PSMA-617 resulted in reduced tumor cell viability (89 ± 4% and 69 ± 7%) when 5 and 10 MBq/mL, respectively, were applied. At lower concentrations of the applied radioligand (0.1–2.5 MBq/mL) the cell viability was unaffected compared to sham-treated control cells. 177Lu-PSMA-617 had a greater effect on tumor cell viability, resulting in 72 ± 1% and 62 ± 3% viable cells after exposure to 5 and 10 MBq/mL, respectively. Also, tumor cell viability was reduced at lower applied activity concentrations of 1.0 and 2.5 MBq/mL resulting in 80 ± 1% and 79 ± 1% viable tumor cells, respectively (Figure 7). It is important to note that, due to the limited availability of 169Er, the experiment could only be performed once in a setting that does not fully reflect the therapeutic potential of this novel radionuclide. The molar activity of 169Er-PSMA-617 was relatively low (10 MBq/nmol), and hence, receptor saturation effects were likely to occur. In order to enable effective cell killing, the radioligand should be prepared at higher molar activity and applied at higher activity concentrations.
Results of PC-3 PIP tumor cell viability study performed with 169Er-PSMA-617 (n = 1, SD refer to intraexperimental variation) and 177Lu-PSMA-617 (n = 3, SD refer to interexperimental variation).
Discussion
In the previous mass separation experiment at the CERN-MEDICIS facility, 169Er was thermally ionized (37). This ionization method, however, was prone to isobaric contamination from elements with similar or lower ionization potential (37). Different studies performed on other radionuclides demonstrated that element-selective laser resonance ionization can provide significantly higher ionization efficiency for the element of interest and, thus, reduce the concentration of isobars in the final product (38, 42). As a result, the surface ionization technique used at MEDICIS was upgraded with a resonant ionization laser ion source. Although higher activities of 169Er were extracted compared to the previous study (169Er activities were increased up to a factor of four) (37), there is still room for further improvement of the overall efficiency and beam purity by developing an ad hoc isotope-selective ionization process for 169Er. The quantity of 168Er target material is several orders of magnitude greater than the 169Er produced; the erbium ionization led to a broad 168Er ion beam after the electromagnet, which tailed on neighboring masses, namely, at mass 169. As one can see from Table 3, it resulted in a prevalence of 168Er over 169Er still after mass separation. A first trial to increase the 169Er isotopic ratio, by narrowing laser linewidth, failed, and the results worsened (collected samples S3 and S4). Furthermore, the parallel ionization of bulk amounts of 168Er can reduce the ion source performance, impeding the proper separator adjustment. This can be solved with the application of an isotope-selective laser ionization scheme or optimization of the mass separator for high-flux ion-beam operation (40).
During the mass separation process, isobaric contaminants can also be extracted due to surface ionization and non-resonant laser ionization. They could also be collected in the Zn-coated gold foils, such as 169Yb, which was observed by γ-ray spectrometry after the mass separation process. The presence of 169Yb would affect the dosimetric evaluation of the 169Er radiopharmaceutical. Moreover, the chemical purity of the final product would have a direct effect on the radiolabeling of the desired radionuclide to a target molecule (56, 57). Thus, a radiochemical separation process was necessary for the separation of 169Er from the isobaric contaminants (169Yb) and soluble residues of the Zn-coated gold foil to make the desired radionuclide available in a purified form suitable for radiolabeling procedures.
As mentioned previously, separation of lanthanides is a particularly challenging issue, due to their similar chemical behavior. Previously, Chakravarty et al. used an electrochemical separation method for the complete removal of 169Er from 169Yb (58). The method was based on a two-step electro-amalgamation technique, the selective reduction of Yb3+ to Yb2+ followed by its preferential amalgamation on to a mercury cathode. To date, considerable effort has been expended on the testing of various chelating agents for lanthanide separation (59). It was shown that α-hydroxy-isobutyric acid (α-HIBA) exhibits a consistent trend across the entire lanthanide series (60–64). In the present study, the complete removal of 169Yb from 169Er was accomplished using Sykam macroporous cation exchange resin and α-HIBA eluent. Zinc separation was achieved using different extraction resins (DGA, LN3, and TK200). It is worth mentioning that the Zn quantity reported in the commercially-available non-carrier-added 177Lu (ITM, Germany) is ≤0.1 μg/GBq with an activity concentration of 37.5 GBq/mL (80 μL 3 GBq 177Lu can contain 0.3 μg Zn). This quantity of Zn does not affect labeling due to the high activity concentration of the 177Lu solution. However, the activity concentration of the mass-separated 169Er solutions are much lower than the commercially-available non-carrier-added 177Lu solution. Thus, even ppb levels of Zn impurity could affect the labeling efficiency (Table 3).
In order to characterize 169Er with regard to its potential as a therapeutic radionuclide, extensive in vitro and in vivo studies will be necessary. In this regard, the stability of DOTA complexes has to be assessed to confirm stable coordination of 169Er using biomolecules that are currently used with 177Lu. This will, however, only be possible once the radionuclide can be made available in larger quantities and at a quality that allows the preparation of radioligands at high molar activity as it is feasible with other therapeutic radionuclides, including 177Lu and 161Tb.
A typical clinical dose of 169Er (Eβav- = 100 keV) is expected to be several GBq, comparable to that of clinically applied 177Lu (Eβav- = 133.6 keV) labeled PSMA-617. As was presented, the activities obtained were sufficient for a preliminary in vitro assay, however, still fall well short for extensive pre-clinical studies. If the overall efficiencies could be improved from 0.5 to 20% (39, 43–45), it will be possible to reach higher 169Er activities. Moreover, for the present study, irradiations were performed for 7 days. For an industrial production, one could irradiate for longer, minimizing the activity loss during transport and chemical separation, and increasing the yield of 169Er.
Conclusion
In this study, radionuclidically pure 169Er was produced at high specific activities by means of neutron irradiation, followed by mass and chemical separation processes, respectively. By combining surface ionization with resonant laser ionization, 169Er activities were increased up to a factor of four compared to the previously-published study. Further developments of the mass separation process, such as the application of an isotope-selective laser ionization scheme and optimization of the mass separator for high-flux ion-beam operation, are needed to increase the overall separation efficiencies and to provide higher activities of 169Er in future. The availability of the β−-particle-emitting 169Er is particularly important to perform pre-clinical studies, in combination with the pure Auger electron emitter 165Er. This combination will help us explore the additional therapeutic effect of Auger electrons to β−-particles, as in the case of 161Tb, which will certainly be of scientific relevance. Enhanced knowledge of the additive therapeutic effects of Auger electrons will likely be well-received by the nuclear medicine community and ought to pave the way toward more efficient cancer treatment, particularly, for the treatment of single cancer cells and small metastases.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Author Contributions
All authors listed have made a substantial contribution to the work, read, and agreed to the published version of the manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors thank CERN ISOLDE and RILIS teams for the laser operation (Maxim D. Seliverstov, Katerina Chrysalidis), radiation protection and logistic teams of PSI (Tobias Schneider) and CERN (Alexandre Dorsival, Matthieu Deschamps and Elodie Aubert, Philippe Bertreix, Nicolas Riggaz, Nabil Menaa, Aurore Boscher, Jeremie Comte, Benjamin Juif); the LARISSA workgroup of Mainz University for the laser preparation and erbium laser ionization scheme development (Prof. Dr. Klaus Wendt and Dr. Dominik Studer). The authors are grateful to Fan Sozzi-Guo, Muhamet Djelili, Alexander Vögele and Walter Hirzel (PSI) and Bernard Crépieux, Giacomo Lunghi, Francesco Riccardi, Miranda Van Stenis, Thomas Schneider (CERN) for technical support.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.643175/full#supplementary-material
ReferencesCutlerCSmithJEhrhardtGTylerTJurissonSDeutschE. Current and potential therapeutic uses of lanthanide radioisotope. Cancer Biother Radiopharm. (2000) 15:531–45. 10.1089/cbr.2000.15.531RöschF. Radiolanthanides in endoradiotherapy: an overview. Radiochim Acta. (2007) 95:303–11. 10.1524/ract.2007.95.6.303UusijärviHBernhardtPRöschFMaeckeHRForssell-AronssonE. Electron and positron emitting radiolanthanides for therapy: aspects of dosimetry and production. J Nucl Med. (2006) 47:807–14.16644751TeoRDTerminiJGrayHB. Lanthanides: applications in cancer diagnosis and therapy miniperspective. J Med Chem. (2016) 59:6012–24. 10.1021/acs.jmedchem.5b01975KostelnikTIOrvigC. Radioactive main group and rare earth metals for imaging and therapy. Chem Rev. (2019) 119:902–56. 10.1021/acs.chemrev.8b0029430379537Van De VoordeMVan HeckeKCardinaelsTBinnemansK. Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications. Coord Chem Rev. (2019) 382:103–25. 10.1016/j.ccr.2018.11.007MüllerCUmbrichtCAGrachevaNTschanVJPellegriniGBernhardtP. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. (2019) 46:1919–30. 10.1007/s00259-019-04345-031134301KratochwilCFendlerWEiberMBaumRBozkurtMFCzerninJ. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. (2019) 46:2536–44. 10.1007/s00259-019-04485-331440799FarahatiJElliottJHöppnerSSteinLGilmanEKummD. Post-radiosynovectomy imaging of Er-169 using scintigraphy and autoradiography. Clin Case Rep. (2017) 5:1048–50. 10.1002/ccr3.98728588871MughabghabSF. Thermal cross sections. Atlas Neutron Reson. (2018) 2:1–19. 10.1016/B978-0-44-463780-2.00001-3RuotsiAHypenMRekonenAOkaM. Erbium-169 versus triamcinolone hexacetonide in the treatment of rheumatoid finger joints. Ann Rheum Dis. (1979) 38:45–7. 10.1136/ard.38.1.45434946DeutschEBrodackJWDeutschKF. Radiation synovectomy revisited. Eur J Nucl Med. (1993) 20:1113–27. 10.1007/BF00173494EANM procedure guidelines for radiosynovectomy. Eur J Nucl Med Mol Imaging. (2003) 30:B12–6. 10.1007/s00259-002-1058-0KahanAMödderGMenkesCJVerrierPDevauxJYBonmartinA. 169Erbium-citrate synoviorthesis after failure of local corticosteroid injections to treat rheumatoid arthritis-affected finger joints. Clin Exp Rheumatol. (2004) 22:722–6.15638046van der ZantFMBoerROMoolenburghDJJahangierZNBijlsmaHJWJJacobsHJWG. Radiation synovectomy with (90)yttrium, (186)rhenium and (169)erbium: a systematic literature review with meta-analyses. Clin Exp Rheumatol. (2009) 27:130–9.19327243KaravidaNNotopoulosA. Radiation synovectomy: an effective alternative treatment for inflamed small joints. Hippokratia. (2010) 14:22–7.20411055ChakrabortySDasTChirayilVLoharSPSarmaHD. Erbium-169 labeled hydroxyapatite particulates for use in radiation synovectomy of digital joints—A preliminary investigation. Radiochim Acta. (2014) 102:443–50. 10.1515/ract-2013-2166KnutL. Radiosynovectomy in the therapeutic management of arthritis. World J Nucl Med. (2015) 14:10. 10.4103/1450-1147.150509CiconeFGnesinSDenoëlTStoraTvan der MeulenNPMüllerC. Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice. EJNMMI Res. (2019) 9:53. 10.1186/s13550-019-0524-731187358BaumRPSinghABenešováMVermeulenCGnesinSKösterU. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. Dalt Trans. (2017) 46:14638–46. 10.1039/C7DT01936J28825750UmbrichtCAKösterUBernhardtPGrachevaNJohnstonKSchibliR. Alpha-PET for prostate cancer: preclinical investigation using 149Tb-PSMA-617. Sci Rep. (2019) 9:1–10. 10.1038/s41598-019-54150-w31780798KuglerE. The ISOLDE facility. Hyperfine Interact. (2000) 129:23–42. 10.1023/A:1012603025802KösterU. ISOLDE target and ion source chemistry. Radiochim Acta. (2001) 89:77777–85. 10.1524/ract.2001.89.11-12.749FedosseevVMarshBFedorovDVKösterUTengbornE. Ionization scheme development at the ISOLDE MLIS. Hyperfine Interact. (2005) 3:1–13. 10.1007/s10751-005-9204-2CatherallRAndreazzaWBreitenfeldtMDorsivalAFockerGJGharsaTP. The ISOLDE facility. J Phys G Nucl Part Phys. (2017) 44:e94002. 10.1088/1361-6471/aa7ebaAllenBJGoozeeGSarkarSBeyerGMorelCByrneAP. Production of terbium-152 by heavy ion reactions and proton induced spallation. Appl Radiat Isot. (2001) 54:53–8. 10.1016/S0969-8043(00)00164-011144253MüllerCZhernosekovKKösterUJohnstonKDorrerHHohnA. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. (2012) 53:1951–9. 10.2967/jnumed.112.10754023139086MüllerCVermeulenCJohnstonKKösterUSchmidRTürlerA. Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging. EJNMMI Res. (2016) 6:35. 10.1186/s13550-016-0189-427108447MüllerCSinghAUmbrichtCAKulkarniHRJohnstonKBenešováM, al. Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Res. (2019) 9:1–10. 10.1186/s13550-019-0538-131346796MüllerCFischerEBeheMKösterUDorrerHHallerS. Future prospects for SPECT imaging using the radiolanthanide terbium-155—production and preclinical evaluation in tumor-bearing mice. Nucl Med Biol. (2014) 41:58–65. 10.1016/j.nucmedbio.2013.11.00224360901MüllerCReberJHallerSDorrerHKösterUJohnstonK. Folate receptor targeted alpha-therapy using terbium-149. Pharmaceuticals. (2014) 7:353–65. 10.3390/ph703035324633429MüllerCVermeulenCKösterUJohnstonKTürlerASchibliR. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. (2016) 1:5. 10.1186/s41181-016-0008-229564382Santos AugustoRStoraTBuehlerLLawsonZMarzariSStachuraM. CERN-MEDICIS (medical isotopes collected from ISOLDE): a new facility. Appl Sci. (2014) 4:265–81. 10.3390/app402026526255495FedosseevVChrysalidisKGoodacreTDMarshBRotheSSeiffertC. Ion beam production and study of radioactive isotopes with the laser ion source at ISOLDE Ion. J Phys G Nucl Part Phys. (2017) 44:1–26. 10.1088/1361-6471/aa78e0GadelshinVCocoliosTFedoseevVHeinkeRKieckTMarchB. Laser resonance ionization spectroscopy on lutetium for the MEDICIS project. Hyperfine Interact. (2017) 238:1–7. 10.1007/s10751-017-1406-xCavaierRFHaddadFSounaletTStoraTZahiI. Terbium radionuclides for theranostics applications: a focus on MEDICIS-PROMED. Phys Procedia. (2017) 90:157–63. 10.1016/j.phpro.2017.09.053Formento-CavaierRKösterUCrepieuxBGadelshinVMHaddadFStoraT. Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy. Nucl Instruments Methods Phys Res Sect B Beam Interact with Mater Atoms. (2019) 463:468–71. 10.1016/j.nimb.2019.04.022GadelshinVMHeinkeRKieckTKronTNaubereitPRöschF. Measurement of the laser resonance ionization efficiency for lutetium. Radiochim Acta. (2019) 107:653–61. 10.1515/ract-2019-3118GadelshinVMBarozierVCocoliosTEFedosseevVNFormento-CavaierRHaddadF. MELISSA: laser ion source setup at CERN-MEDICIS facility. Blueprint. Nucl Instruments Methods Phys Res Sect B Beam Interact with Mater Atoms. (2020) 463:460–3. 10.1016/j.nimb.2019.04.024GadelshinVMWilkinsSFedosseevVNBarberoEBarozierVBernardesAP. First laser ions at the CERN-MEDICIS facility. Hyperfine Interact. (2020) 241:1–9. 10.1007/s10751-020-01718-yKösterU. Resonance ionization laser ion sources. Nuc Phys A. (2002) 701:441–51. 10.1016/S0375-9474(01)01625-624593628WendtKDABlaumKGeppertCHornRPasslerGTrautmannN. Laser resonance ionization for efficient and selective ionization of rare species. Nucl Instruments Methods Phys Res Sect B Beam Interact with Mater Atoms. (2003) 204:325–30. 10.1016/S0168-583X(02)01936-5KieckTDorrerHDüllmannCEGadelshinVSchneiderFWendtK. Highly efficient isotope separation and ion implantation of 163Ho for the ECHo project. Nucl Instruments Methods Phys Res Sect A Accel Spectrometers Detect Assoc Equip. (2019) 945:162602. 10.1016/j.nima.2019.162602StuderDDyraufPNaubereitPHeinkeRWendtK. Resonance ionization spectroscopy in dysprosium: excitation scheme development and re-determination of the first ionization potential. Hyperfine Interact. (2017) 238:1–11. 10.1007/s10751-016-1384-4TalipZReinkeRChevallayEChrysalidisKCocoliosETDucheminC. Efficient Production of High Specific Activity 167Tm at PSI and CERN-MEDICIS, PSI-LRC 2020 Annual Report (2021). p 52. Available online at: https://www.psi.ch/en/lrc/annual-reports (accessed April 9, 2021).NedjadiYBailatCCaffariYCassettePBochudF. Set-up of a new TDCR counter at IRA-METAS. Appl Radiat Isot. (2015) 97:113–7. 10.1016/j.apradiso.2014.12.02325569200MattolatCRotheSSchwellnusFGottwaldTRaederSWendtK. An all-solid-state high repetiton rate titanium: sapphire laser system for resonance ionization laser ion sources. AIP Conf Proc. (2009) 1104:114–9. 10.1063/1.3115586LassenJLiRRaederSZhaoXDekkerTHeggenH. Current developments with TRIUMF's titanium-sapphire laser based resonance ionization laser ion source: an overview. Hyperfine Interact. (2017) 238:1–9. 10.1007/s10751-017-1407-9BenešováMUmbrichtCASchibliRMüllerC. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. (2018) 15:934–46. 10.1021/acs.molpharmaceut.7b0087729400475BanerjeeSRNgenEJRotzMWKakkadSLisokAPracittoR. Synthesis and evaluation of GdIII-based magnetic resonance contrast agents for molecular imaging of prostate-specific membrane antigen. Angew Chemie Int Ed. (2015) 54:10778–82. 10.1002/anie.201503417BanerjeeSRPullambhatlaMFossCANimmagaddaSFerdaniRAndersonCJ. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. (2014) 57:2657–69. 10.1021/jm401921jUmbrichtCABenešováMSchibliRMüllerC. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. (2018) 15:2297–306. 10.1021/acs.molpharmaceut.8b0015229684274DeberleLMBenešováMUmbrichtCABorgnaFBüchlerMZhernosekovK. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. (2020) 10:1678–93. 10.7150/thno.4048232042329BisiATerraniSZappaL. An investigation of the first rotational level of 169Tm. Nuova Cim. (1956) 4:758–63. 10.1007/BF02746165TalipZFavarettoCGeistlichSvan der MeulenNP. A Step-by-step guide for the novel radiometal production for medical applications: case studies. Molecules. (2020) 25:966. 10.3390/molecules2504096632093425BreemanWAPJongM DeVisserTJErionJLKrenningEP. Occasional survey Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. (2003) 30:917–20. 10.1007/s00259-003-1142-0AstiMTegoniMFarioliDIoriMGuidottiCCutlerCS. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions. Nucl Med Biol. (2012) 39:509–17. 10.1016/j.nucmedbio.2011.10.01522172388ChakravartyRChakrabortySChirayilVDashA. Reactor production and electrochemical purification of 169Er: a potential step forward for its utilization in in vivo therapeutic applications. Nucl Med Biol. (2014) 41:163–70. 10.1016/j.nucmedbio.2013.11.009NashKLJensenMP. Analytical separations of the lanthanides: basic chemistry and methods. Handb Phys Chem Rare Earths. (2000) 28:311–71. 10.1016/S0168-1273(00)28008-2BearJLChoppinGRQuaglianoJV. Complexes of the lanthanide elements with mercaptocarboxylate ligands. J Inorg Nucl Chem. (1963) 25:513–8. 10.1016/0022-1902(63)80235-3PourjavidMRNorouziPGanjaliMRNematiAZamaniHAJavaheriM. Separation and determination of medium lanthanides: a new experiment with use of ion-exchange separation and fast fourier transform continuous cyclic voltammetry. Int J Electrochem Sci. (2009) 4:1650–71.RautNMJaisonPGAggarwalSK. Comparative evaluation of three α-hydroxycarboxylic acids for the separation of lanthanides by dynamically modified reversed-phase high-performance liquid chromatography. J Chromatogr A. (2002) 959:163–72. 10.1016/S0021-9673(02)00447-812141542TalipZPfisterSDresslerRDavidJCVögeleAVontobelP. Analysis of the 148Gd and 154Dy content in Proton- Irradiated Lead Targets. Anal Chem. (2017) 89:6861–9. 10.1021/acs.analchem.7b0135328528549ChieraNMTalipZFankhauserASchumannD. Separation and recovery of exotic radiolanthanides from irradiated tantalum targets for half-life measurements. PLoS ONE. (2020) 15:e0235711. 10.1371/journal.pone.023571132645091
1https://www.nndc.bnl.gov/nudat2/ (accessed March 3, 2021).
Funding. ZT and NM received funding from the Swiss National Science Foundation (SNF Grant Number: 200021_188495). CM obtained funding for this project from the Swiss Cancer Research (KFS-4678-02-2019-R). FB received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No 701647.